生命科学资讯

Ultragenyx lays off 10% of workforce as FDA continues to stall gene therapy approval plans

'When the markets opened, we were ready': Why biotech IPOs are back for 2026

Icon shares plummet after CRO reveals accounting investigation, pulls 2025 guidance

Lundbeck’s migraine prevention treatment sees ph. 2 success after trial’s earlier setback

BridgeBio preps approval push after dwarfism drug increases children's height in phase 3

Langer-backed biotech looks to end cancer recurrence with surgical revolution

Agilent companion diagnostic lands FDA nod alongside Keytruda's latest cancer approval

Seres to lay off 30% of employees, pause lead program in latest strategic shift

Sanofi ousts Paul Hudson after ‘bumpy ride’, poaches Merck KGaA CEO to lead the French pharma

European VCs join forces to boost flagging biotech investment in the region

UPDATE: After Moderna's rebuke, HHS stands behind FDA decision to spurn mRNA flu filing

Takeda downsizes Boston footprint amid consolidation effort

‘The only thing that saves us is data’: Allogeneic CAR-T biotechs fight for relevance as industry moves on

Upstream posts Tezspire-like asthma efficacy in phase 2 but falls short of best-case scenario

Madrigal pens $4.4B deal for Ribo's preclinical siRNA programs in latest Rezdiffra MASH play

GE HealthCare debuts tech to help hospitals remotely maintain bedside ECG stations

Moderna hit with FDA refusal-to-file letter for mRNA flu shot, issues sharp rebuke of agency's rationale